Table 1 Clinical and pathological features of 26 patients with Pancreatic Ductal Adenocarcinoma treated with Gemcitabine after pancreatic resection

Age at diagnosis (years), median (Q1-Q3)

64.5 (51?73)

Gender, male/female (%male)

17/9 (65)

Smoking habit, n (%)

?No

10 (48)

?Yes

8 (38)

?Ex

3 (14)

Missing information

5

Alcohol Use, n (%)

?No

18 (95)

?Yes

1 (5)

Missing information

7

Jaundice, y/n (%y)

15/11 (58)

Diabetes mellitus, y/n (%y)

9/17 (35)

Familial*, y/n (%y)

5/21 (19)

Previous Neoplasia, y/n (%y)

2/24 (8)

Preoperative serum CAE levels (ng/ml), median (Q1-Q3)

3.2 (2.0-6.0)

Preoperative serum CA 19?9 levels (U/ml), median (Q1-Q3)

200.4 (53.5-335.9)

Size (cm), median (Q1-Q3)

3 (2.4-3.5)

Tumour type, n (%)

?Adenocarcinoma

22 (85)

?Adenocarcinoma Mucinous

4 (15)

Tumour grading, n (%)

?G1: well differentiated

5 (20)

?G2: moderately differentiated

10 (40)

?G3: poorly differentiated

10 (40)

Missing information

1

T: Tumour size, n (%)

?T1

1 (4)

?T2

2 (8)

?T3

23 (88)

N: regional lymph nodes, n (%)

?N0

3 (12)

?N1

23 (88)

Lymph nodes ratio, median (Q1-Q3)

0.24 (0.07-0.47)

Tumour stage, n (%)

?IIA

3 (12)

?IIB

23 (88)

Perineural Invasion, y/n (% y)

14/12 (54)

Vascular Invasion, y/n (% y)

3/23 (12)

Margins of resection, n (%)

?R0: negative resection margins

18 (69)

?R1: microscopic positive resection margins

8 (31)

Postoperative serum CAE levels (ng/ml), median (Q1-Q3)

3.4 (2.0-4.5)

Postoperative serum CA 19?9 levels (U/ml), median (Q1-Q3)

10.4 (7.3-36.2)

Treatment with Gemcitabine

?Nr. Cycles, median (Q1-Q3)

5 (3?7)

?Nr. Cycles?<?6, n (%)

10 (39)

Nr. Cycles?>?6, n (%)

16 (62)

Overall Follow-up (yrs), median (Q1-Q3)

1.4 (0.9-2.3)

Disease progression Follow-up (yrs), median (Q1-Q3)

0.9 (0.6-1.3)

Mortality rate**

16/45 (35)

Disease Progression rate**

17/29 (58)